4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Zentalis Pharmaceuticals, Inc. (ZNTL) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 106 employees. Its market capitalization is roughly $335 million. In the fiscal year ended 2025-12-31, ZNTL reported $0M in revenue and ($137M) in net income.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $67M | $0M | $0M | — |
| Operating Income (EBIT) | ($145M) | ($188M) | ($254M) | ($227M) | — |
| Net Income | ($137M) | ($166M) | ($292M) | ($237M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($38M) | ($37M) | ($34M) | ($36M) | ($38M) | — |
| Net Income | ($35M) | ($35M) | ($27M) | ($27M) | ($48M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $289M | $430M | $552M | $539M | — |
| Total Liabilities | $73M | $93M | $114M | $105M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ZNTL viewer.
About TickerBase · Data methodology & sources